[EN] CYCLOALKYL NITRILE PYRAZOLO PYRIDONES AS JANUS KINASE INHIBITORS [FR] CYCLOALKYLNITRILE PYRAZOLOPYRIDONES UTILISÉES COMME INHIBITEURS DE LA JANUS KINASE
[EN] ACYCLIC CYANOETHYLPYRAZOLO PYRIDONES AS JANUS KINASE INHIBITORS<br/>[FR] CYANOÉTHYLPYRAZOLO PYRIDONES ACYCLIQUES EN TANT QU'INHIBITEURS DE JANUS KINASE
申请人:MERCK SHARP & DOHME
公开号:WO2014146493A1
公开(公告)日:2014-09-25
The instant invention provides compounds of formula I which are JAK inhibitors, and as such are useful for the treatment of JAK-mediated diseases such as rheumatoid arthritis, asthma, COPD and cancer.
[EN] CYCLOALKYL NITRILE PYRAZOLO PYRIDONES AS JANUS KINASE INHIBITORS<br/>[FR] PYRIDONES CYCLOALKYLE PYRAZOLO NITRILE EN TANT QU'INHIBITEURS DE JANUS KINASE
申请人:MERCK SHARP & DOHME
公开号:WO2014146246A1
公开(公告)日:2014-09-25
The instant invention provides compounds of formula I which are JAK inhibitors, and as such are useful for the treatment of JAK-mediated diseases such as rheumatoid arthritis, asthma, COPD and cancer.
[EN] GEMINALLY SUBSTITUTED CYANOETHYLPYRAZOLO PYRIDONES AS JANUS KINASE INHIBITORS<br/>[FR] CYANOÉTHYLPYRAZOLOPYRIDONES À SUBSTITUTION GÉMINALE UTILISÉES COMME INHIBITEURS DE LA JANUS KINASE
申请人:MERCK SHARP & DOHME
公开号:WO2014146491A1
公开(公告)日:2014-09-25
The instant invention provides compounds of Formula (I) which are JAK inhibitors, and as such are useful for the treatment of JAK-mediated diseases such as rheumatoid arthritis, asthma, COPD and cancer.
[EN] N-(2-CYANO HETEROCYCLYL)PYRAZOLO PYRIDONES AS JANUS KINASE INHIBITORS<br/>[FR] N-(2-CYANO-HÉTÉROCYCLYL)PYRAZOLO-PYRIDONES EN TANT QU'INHIBITEURS DE LA JANUS KINASE
申请人:MERCK SHARP & DOHME
公开号:WO2014146492A1
公开(公告)日:2014-09-25
Provided are compounds of Formula I, a JAK inhibitor, and use thereof for the treatment of JAK-mediated diseases by the application.
提供了公式I的化合物,一种JAK抑制剂,以及其在治疗JAK介导疾病中的应用。
N-(2-CYANO HETEROCYCLYL) PYRAZOLO PYRIDONES AS JANUS KINASE INHIBITORS
申请人:DINSMORE Christopher
公开号:US20160272633A1
公开(公告)日:2016-09-22
Provided are compounds of Formula I, a JAK inhibitor, and use thereof for the treatment of JAK-mediated diseases by the application.